Health Condition 1: I251- Atherosclerotic heart disease of native coronary artery Health Condition 2: E119- Type 2 diabetes mellitus without complications
Conditions
Interventions
Intervention1: Vitamin D
: Dose:60000 IU
Frequency: Vitamin D 60000 IU/weeks administered orally from day 1 to end of the three months and from 4th month to 12th month subjects will receive 60000 IU/m
Sponsors
National Institute of Pharmaceutical Education and ResearchGuwahati
Eligibility
Inclusion criteria
Inclusion criteria: Inclusion criteria for Type 2 diabetes group Age > 25 to 65 years Male and female patients included HbA1C levels >=7 % to Total 25 (OH) D levels Inclusion criteria for Type 2 diabetes with coronary artery diseases (T2DM_CAD) Age > 25 to 65 years Male and female patients included HbA1C levels >=7 % to Documented acute myocardial infarction, narrowing, or blockage of one or more epicardial coronary artery with greater than 25% stenosis shown in coronary angiography and diagnosed by cardiologists.
Exclusion criteria
Exclusion criteria: Exclusion Criteria for Type 2 diabetes group SBP/DBP >=140/100 mmHg. Subjects on Insulin therapy Prior vitamin D therapy Subjects with any cardiovascular complications and chronic diseases Exclusion Criteria for Type 2 diabetes with coronary artery diseases (T2DM_CAD) Exclusion criteria defined for this study is prior treatment with vitamin D, clinical or laboratory evidence of liver failure, renal failure (plasma creatinine levels > 1.5 mg/dl), Type 1 diabetes, cancer, thyroid disease, and pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Glycaemic control Cardiac function Timepoint: one year | — |
Secondary
| Measure | Time frame |
|---|---|
| Immune modulation Modulation of platelet mediated inflammation Timepoint: One year | — |
Countries
India
Contacts
Public ContactDr Rupam Das
National Institute of Pharmaceutical Education and Research Guwahat
Outcome results
None listed